All News
Abstract 2360: Single-center lupus pregnancy cohort found that:
🔹 Absence of DORIS remission associated w/ adverse pregnancy outcomes (Pre-term, Pre-eclampsia)
🔹 This is along with known risk factors: antihypertensive use, prior nephritis, active disease
@RheumNow #ACR25 https://t.co/STg1NBeFPo
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
CDAI appropriately guided therapy escalation in RA, but not for everyone. Treatment adjustments were less likely in pts with public or no insurance. Even data-driven care can fall short when access barriers persist.
@RheumNow #ACR25 Abstract#2616
Jiha Lee JihaRheum ( View Tweet)
Reaadmissions in sle pregnancies from 66k patients
Insurance and economics seem to be very important in predictions using machine learning.
Abst#2629 #ACR25 @RheumNow https://t.co/x2oo9TOxoh
Bella Mehta bella_mehta ( View Tweet)
In healthy women, preeclampsia was more common with:
- increased calprotectin
- decreased anti-CCP (very low levels)
during pregnancy
& this has good predictive capacity for future preeclampsia. Rheum pathophys can give insights into adjacent pathology
#ACR25 ABST2628 @RheumNow https://t.co/7d5YB6n6XJ
Links:
David Liew drdavidliew ( View Tweet)
In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleeding vs TNFi, but lower malignancy risk. Infection rates were similar, with a trend toward more herpes zoster in JAKi users. Abstract#2633 @RheumNow #ACR25 https://t.co/pPY0wpAKA3
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Anti ccp may be protective for preeclampsia (secondary to NETs)
Abst#2628 @RheumNow #ACR25 https://t.co/n3ge0iIiB0
Links:
Bella Mehta bella_mehta ( View Tweet)
DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort.
We’re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful
#ACR25 ABST2627 @RheumNow https://t.co/oDOpySGS3N
David Liew drdavidliew ( View Tweet)
Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rheumatic diseases.
Abst#2627 #ACR25 @RheumNow https://t.co/T9Ll1FNjT7
Links:
Bella Mehta bella_mehta ( View Tweet)
Predictors of retinopathy progression after HCQ discontinued?
In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c
Age - significant assoc'n with progression
✳️monitor toxicity more closely esp in older pts
#ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ
sheila RHEUMarampa ( View Tweet)
A new IA drug in OA 🚨
Cell therapy of apoptotic PBMCs ENX-CL-05-001
RCT Ph2A moderate to severe OA
134 pts 3 injections vs. PBO
Pain improvement 24%
Better response in people > 60 and more so 65yo
Potential improvement for > 6mo
Safety mainly local reactions to compound https://t.co/m2MZN3i22b
Aurelie Najm AurelieRheumo ( View Tweet)
Lung Ultrasound in CTD-ILD
Prospective cohort 146 pts CTD-ILD
30 preclinical ILD
76 limited ILD
40 extensive ILD
Median LUS scores higher if Extensive ILD
LUS scores correlation w/ fibrosis severity, DLCO & FCV
Agreement between LUS and HRCT severity 0.74
Excellent inter https://t.co/R9zGmCTT8Q
Aurelie Najm AurelieRheumo ( View Tweet)
Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO
Mos. 4-6: >10% improvement in alopecia w/Cenerimod
Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod
Early improvement in alopecia & ulcers w/Cenerimod
Promising?
#ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr
sheila RHEUMarampa ( View Tweet)
#ACRBest @RheumNow https://t.co/SP3tib5tL1
Aurelie Najm AurelieRheumo ( View Tweet)
52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA
Primary ACR 50 16wks
Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW
ACR50 50% 57% 51%
ACR70 36% 42% 42%
PASI100 55% 64% 58%
MDA 47% 52% 47%
No specific enthesitis data presented
No new safety signal
Next https://t.co/J18rSTmyze
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#2601 At single cell level using CyTOF, metabolic activity varied btw HC & autoimmune groups but clusters in At-Risk ANA+ve appeared closer to #SLE. ANA+ve who progressed to AI-CTD showed Plasmablast expansion & enhanced glycolysis. Could be used as target @RheumNow https://t.co/jtrM1wvQLk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What's new in sjogren's?
Promising phase III data of telitacicept (dual BLyS + APRIL neutralization)
Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose
Similar rates of adverse events
@RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Gut microbiome on Urate metabolism study- 1500 men and women.
From 3 cohorts- Framingham, nurses health and men's lifestyle with blood and stool data
Focused on 5 urate metbolizing genes
Abst#2590 #ACR25 @RheumNow https://t.co/YxBb3WfcbB
Bella Mehta bella_mehta ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Is AI Smarter than a Doctor?
Dr. Janet Pope reviews key takeaways from the session, "Artificial Intelligence in Medical Education: From Theory to Practice," at #ACR25.
https://t.co/F6KEYAWi75 https://t.co/m57asdLGrn
Dr. John Cush RheumNow ( View Tweet)
#1748 Higher air pollution, esp PM2.5, linked to ⬆️RA disease activity and more flares in >1000 Korean patients. Each rise in PM2.5 significantly boosted DAS28, CDAI & joint counts.
Does cleaner air mean calmer joints?
@RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
